Study Populations Sample Clauses
The 'Study Populations' clause defines the specific groups of individuals who are eligible to participate in a research study. It typically outlines inclusion and exclusion criteria, such as age range, medical condition, or other demographic and clinical characteristics that participants must meet. By clearly specifying who can and cannot be enrolled, this clause ensures that the study results are relevant to the intended population and helps maintain the scientific validity and ethical standards of the research.
Study Populations. We used the genetic data from the UK Biobank (UKB), a large-scale population-based prospective cohort study of approximately 500,000 individuals aged 40-69 years at recruitment across the United Kingdom between March 2006 and October 2010. The ethical collection of sample and full details of the genotyping and imputation are described elsewhere [14], [15]. Our study populations for each of the three disease outcomes are defined as follows: • The breast cancer eligible population was women who had not had breast cancer, carcinoma in situ or mastectomy prior to baseline. • For the hypertension eligible population, we excluded individuals with missing or implausible systolic blood pressure (SBP) measurements (< 70 or > 270 mmHg) at baseline, and those with prior Major Adverse Cardiovascular Events (▇▇▇▇). • The dementia eligible population was restricted to individuals without prior diagnosis of dementia or Alzheimer’s disease. Disease ascertainment of UKB during the following-up period utilised linkage to death registry, cancer registry, and Hospital Episode Statistics (HES). Hypertension is defined as SBP>=140 at baseline; the International Classification of Diseases (ICD) code for breast cancer and dementia can be found in Supplementary Tables 13-15.
Study Populations. The UN and WHO classify adolescence as a period of development and transition in between childhood and adulthood, between the ages of 10- to 19-years-old (WHO, 2017). In addition, “young people” are those aged 10 to 24, and “youth” are those aged 15 to 24 years (UN General Assembly, 1981). Our target population was adolescent girls and young adult women between the ages of 10 to 24 at the time the outcome was measured. We examined GBV exposures occurring in childhood and adolescence and young adulthood. Using the World Bank classifications of country income levels (World Bank, 2017), we focused on LMICs (including lower middle and upper middle) for this review. Specific country names, as well as general terms, such as “developing country,” were used (Table 2). Refugees from LMICs and resettled populations in high-income countries were not included. Because of the difficulties to group shared experiences due to different contextual factors, resettled and refugee populations and their experiences with GBV and SRH required their own systematic review of reviews. Table 2 displays the final search strings and search results for all three databases. The authors employed a systematic search strategy using PubMed and PsycINFO electronic databases on November 1, 2016. The PsycINFO search yielded no reviews that matched the
Study Populations. We used the genetic data from the UK Biobank (UKB), a large-scale population-based prospective cohort study of approximately 500,000 individuals aged 40-69 years at recruitment across the United Kingdom between March 2006 and October 2010. Full details of the genotyping and imputation are described elsewhere (▇▇▇▇▇▇▇ et al., 2018). Our study populations for each of the three disease outcomes are defined as follows: • The breast cancer eligible population was women who had not had breast cancer, carcinoma in situ or mastectomy prior to baseline. • For the hypertension eligible population, we excluded individuals with missing or implausible systolic blood pressure (SBP) measurements (< 70 or > 270 mmHg) at baseline, and those with prior Major Adverse Cardiovascular Events (▇▇▇▇). • The dementia eligible population was restricted to individuals without prior diagnosis of dementia or Alzheimer’s disease. Disease ascertainment of UKB during the following-up period utilised linkage to death registry, cancer registry, and Hospital Episode Statistics (HES). Hypertension is defined as SBP>=140 at baseline; the International Classification of Diseases (ICD) code for breast cancer and dementia can be found in Supplementary Tables 13-15.
Study Populations. The following study populations are defined for analysis: Intention-to-treat (ITT) and Safety.
Study Populations. The PK Population will consist of all subjects who have received a dose of study drug, have at least 1 quantifiable plasma concentration, and for whom at least 1 PK parameter can be computed. A subject may be excluded from the PK summary statistics and statistical analysis if the subject has an AE of vomiting that occurs at or before 2 times median time to maximum concentration. The impact of protocol deviations on PK population will be evaluated on a case-by-case basis. The Safety Population will consist of all subjects who have received at least 1 dose of study drug. Subjects will be classified into groups based on actual treatment received.
Study Populations. There will be two study populations: the modified Intent-to-Treat (mITT) and Immunogenicity populations. The mITT population will include any participant who was enrolled, randomized, and received at least one vaccine. The Immunogenicity Population is a subset of the mITT Population that includes only subjects who received at least one vaccine, provide visit 1 and visit 2 blood draws available for analysis within the protocol-defined time frame, and with no protocol violations affecting immunogenicity. These protocol violations will be listed in the Statistical Analysis Plan. Statistical analyses of safety outcomes will be performed for the mITT population, and immunogenic outcomes will be analyzed for the Immunogenicity Population.